<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Neurol.</journal-id>
<journal-title-group>
<journal-title>Frontiers in Neurology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Neurol.</abbrev-journal-title>
</journal-title-group>
<issn pub-type="epub">1664-2295</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fneur.2025.1737566</article-id>
<article-version article-version-type="Version of Record" vocab="NISO-RP-8-2008"/>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Research</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>White matter hyperintensity burden in young patent foramen ovale patients and its correlation with migraine</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Li</surname>
<given-names>Yuxuan</given-names>
</name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<xref ref-type="author-notes" rid="fn0002"><sup>&#x2020;</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Liu</surname>
<given-names>Yangyingqiu</given-names>
</name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<xref ref-type="author-notes" rid="fn0002"><sup>&#x2020;</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/832027"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Cao</surname>
<given-names>Jinfeng</given-names>
</name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/2918094"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &#x0026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &#x0026; editing</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Shang</surname>
<given-names>Qun</given-names>
</name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zheng</surname>
<given-names>Wenjing</given-names>
</name>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
<xref ref-type="aff" rid="aff4"><sup>4</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Li</surname>
<given-names>Jiaqi</given-names>
</name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<xref ref-type="aff" rid="aff4"><sup>4</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Shi</surname>
<given-names>Xinying</given-names>
</name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<xref ref-type="aff" rid="aff4"><sup>4</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Xin</surname>
<given-names>Jiaxiang</given-names>
</name>
<xref ref-type="aff" rid="aff5"><sup>5</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhao</surname>
<given-names>Wei</given-names>
</name>
<xref ref-type="aff" rid="aff6"><sup>6</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Meng</surname>
<given-names>Ye</given-names>
</name>
<xref ref-type="aff" rid="aff7"><sup>7</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Li</surname>
<given-names>Bo</given-names>
</name>
<xref ref-type="aff" rid="aff8"><sup>8</sup></xref>
<xref ref-type="corresp" rid="c001"><sup>&#x002A;</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/1947152"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &#x0026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &#x0026; editing</role>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Luo</surname>
<given-names>Xin</given-names>
</name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<xref ref-type="corresp" rid="c001"><sup>&#x002A;</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/875742"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &#x0026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &#x0026; editing</role>
</contrib>
</contrib-group>
<aff id="aff1"><label>1</label><institution>School of Medical Imaging, Shandong Second Medical University</institution>, <city>Weifang</city>, <country country="cn">China</country></aff>
<aff id="aff2"><label>2</label><institution>Department of Radiology, Zibo Central Hospital</institution>, <city>Zibo</city>, <country country="cn">China</country></aff>
<aff id="aff3"><label>3</label><institution>Department of Imaging, Leling People's Hospital</institution>, <city>Dezhou</city>, <country country="cn">China</country></aff>
<aff id="aff4"><label>4</label><institution>School of Medical Imaging, Binzhou Medical University</institution>, <city>Yantai</city>, <country country="cn">China</country></aff>
<aff id="aff5"><label>5</label><institution>MR Research Collaboration, Siemens Healthineers Ltd.</institution>, <city>Shanghai</city>, <country country="cn">China</country></aff>
<aff id="aff6"><label>6</label><institution>Department of Ultrasound, Zibo Central Hospital</institution>, <city>Zibo</city>, <country country="cn">China</country></aff>
<aff id="aff7"><label>7</label><institution>Department of Neurology, Zibo Central Hospital</institution>, <city>Zibo</city>, <country country="cn">China</country></aff>
<aff id="aff8"><label>8</label><institution>Department of Cardiology, Zibo Central Hospital</institution>, <city>Zibo</city>, <country country="cn">China</country></aff>
<author-notes>
<corresp id="c001"><label>&#x002A;</label>Correspondence: Xin Luo, <email xlink:href="mailto:asd0601@126.com">asd0601@126.com</email>; Bo Li, <email xlink:href="mailto:libosubmit@163.com">libosubmit@163.com</email></corresp>
<fn fn-type="equal" id="fn0002"><label>&#x2020;</label><p>These authors have contributed equally to this work</p></fn>
</author-notes>
<pub-date publication-format="electronic" date-type="pub" iso-8601-date="2026-01-02">
<day>02</day>
<month>01</month>
<year>2026</year>
</pub-date>
<pub-date publication-format="electronic" date-type="collection"><year>2025</year>
</pub-date>
<volume>16</volume>
<elocation-id>1737566</elocation-id>
<history>
<date date-type="received">
<day>02</day>
<month>11</month>
<year>2025</year>
</date>
<date date-type="rev-recd">
<day>30</day>
<month>11</month>
<year>2025</year>
</date>
<date date-type="accepted">
<day>08</day>
<month>12</month>
<year>2025</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#x00A9; 2026 Li, Liu, Cao, Shang, Zheng, Li, Shi, Xin, Zhao, Meng, Li and Luo.</copyright-statement>
<copyright-year>2026</copyright-year>
<copyright-holder>Li, Liu, Cao, Shang, Zheng, Li, Shi, Xin, Zhao, Meng, Li and Luo</copyright-holder>
<license>
<ali:license_ref start_date="2026-01-02">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
<license-p>This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License (CC BY)</ext-link>. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>
</license>
</permissions>
<abstract>
<sec>
<title>Objective</title>
<p>Patent foramen ovale (PFO) may play an important role in the progression of white matter hyperintensity (WMH) through paradoxical embolism-induced chronic cerebral microcirculatory dysfunction. WMH is closely associated with the pathogenesis of migraine. This study aims to investigate the burden of WMH in young patients with PFO and their potential association with migraine.</p>
</sec>
<sec>
<title>Methods</title>
<p>A retrospective analysis was conducted involving 47 young patients with PFO (PFO group) and 50 healthy controls (HC group). The Headache Impact Test-6 (HIT-6), Migraine Disability Assessment (MIDAS), and Visual Analogue Scale (VAS) scores were recorded to assess the severity of migraine. Conventional MRI was utilized to evaluate periventricular hyperintensity (PVH) and deep white matter hyperintensity (DWMH) grades, and the differences were compared between groups. Correlations among laboratory indicators, right-to-left shunt (RLS) grade, PFO diameter, WMH burden, and migraine severity were examined in PFO patients.</p>
</sec>
<sec>
<title>Results</title>
<p>The PVH and DWMH scores were significantly higher in the PFO group than in HC (<italic>p</italic>&#x202F;&#x003C;&#x202F;0.001). PFO diameter and RLS grade both showed positive correlations with PVH, DWMH, VAS, MIDAS and HIT-6 scores (<italic>p</italic>&#x202F;&#x003C;&#x202F;0.05). The grades of PVH and DWMH were significantly positively correlated with the HIT-6, VAS, and MIDAS scores (<italic>p</italic>&#x202F;&#x003C;&#x202F;0.001). PFO diameter was an independent predictor of PVH and DWMH grades (<italic>p</italic>&#x202F;&#x003C;&#x202F;0.001).</p>
</sec>
<sec>
<title>Conclusion</title>
<p>Young PFO patients exhibit an increased WMH burden, and PFO diameter serves as an independent risk factor for WMH grade. These findings suggest that PFO may contribute to the development of WMH in young individuals, potentially through mechanisms involving paradoxical embolism and chronic cerebral hypoperfusion. In young patients with PFO and migraine, monitoring WMH burden via neuroimaging may provide insights for future personalized management strategies.</p>
</sec>
</abstract>
<kwd-group>
<kwd>cryptogenic stroke</kwd>
<kwd>migraine</kwd>
<kwd>patent foramen ovale</kwd>
<kwd>right-to-left shunt</kwd>
<kwd>white matter hyperintensity</kwd>
</kwd-group>
<funding-group>
<funding-statement>The author(s) declared that financial support was received for this work and/or its publication. This work was supported by the Natural Science Foundation of Shandong Province (Grant no. ZR2025QC967).</funding-statement>
</funding-group>
<counts>
<fig-count count="4"/>
<table-count count="3"/>
<equation-count count="0"/>
<ref-count count="34"/>
<page-count count="8"/>
<word-count count="5676"/>
</counts>
<custom-meta-group>
<custom-meta>
<meta-name>section-at-acceptance</meta-name>
<meta-value>Headache and Neurogenic Pain</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec sec-type="intro" id="sec1">
<label>1</label>
<title>Introduction</title>
<p>Patent foramen ovale (PFO) is the primary cause of right-to-left shunt (RLS), which is present in approximately 25&#x2013;30% of the general population, with a notable increase to about 40% among individuals with cryptogenic stroke (CS) (<xref ref-type="bibr" rid="ref1 ref2 ref3">1&#x2013;3</xref>).</p>
<p>White matter hyperintensities (WMH) are areas of elevated signal intensity observed on brain magnetic resonance imaging (MRI) fluid-attenuated inversion recovery (FLAIR) sequences. They are associated with an elevated risk of future stroke, increased stroke severity, cognitive decline, and mortality, and have been identified as predictors of stroke, cognitive decline, and depression (<xref ref-type="bibr" rid="ref4">4</xref>, <xref ref-type="bibr" rid="ref5">5</xref>).</p>
<p>The PFO facilitates a pathological mechanism for paradoxical embolism, wherein emboli originating from the venous system gain access to the arterial circulation. Current evidence suggests a correlation between PFO-related paradoxical embolism and an elevated risk of WMH (<xref ref-type="bibr" rid="ref6">6</xref>). Additionally, research has demonstrated that cerebral microinfarcts in specific parts of the brain are linked to the presence of PFO, thereby reinforcing the association between PFO-related microembolic events and damage to brain tissue (<xref ref-type="bibr" rid="ref6">6</xref>).</p>
<p>The WMH is recognized as a biomarker for chronic migraine (<xref ref-type="bibr" rid="ref7">7</xref>). The likelihood of developing WMH in individuals with migraine is two to four times greater than in the general population (<xref ref-type="bibr" rid="ref8">8</xref>), and this correlation may be significantly associated with the RLS (<xref ref-type="bibr" rid="ref9">9</xref>). The proposed underlying mechanism suggests that RLS may permit microemboli or vasoactive substances from the venous system to circumvent the pulmonary circulation&#x2019;s filtration function, thereby entering the cerebral arterial circulation directly. This process could potentially damage cerebral white matter, and subsequently result in the formation of WMH (<xref ref-type="bibr" rid="ref9">9</xref>).</p>
<p>The RLS grade is primarily used to evaluate the severity of RLS (<xref ref-type="bibr" rid="ref10">10</xref>), and PFO diameter is a crucial factor in assessing its severity and clinical implications (<xref ref-type="bibr" rid="ref11">11</xref>). Although the PFO diameter and RLS are associated with WMH occurrence (<xref ref-type="bibr" rid="ref12">12</xref>), no clear evidence indicates that PFO diameter or RLS severity directly leads to WMH aggravation. The underlying pathophysiological mechanism necessitates further investigation to validate the hypothesis that PFO facilitates the entry of microemboli or vasoactive substances into the brain, triggering chronic microcirculatory dysfunction, which in turn leads to the formation and progression of WMH.</p>
<p>Currently, there is a lack of systematic research on the quantitative relationship among PFO diameter, RLS grade, WMH burden, and migraine severity in young PFO patients. Therefore, this study investigates young PFO patients to minimize age-related confounding effects. By distinguishing and grading WMH in different locations, include periventricular and deep white matter, it aims to elucidate the quantitative relationships among PFO diameter, RLS grade, WMH burden, and migraine severity.</p>
</sec>
<sec sec-type="materials|methods" id="sec2">
<label>2</label>
<title>Materials and methods</title>
<sec id="sec3">
<label>2.1</label>
<title>Patient population</title>
<p>This study received approval from the Ethics Committee of Zibo Central Hospital (Approval No. 2024219). As a retrospective study, it was exempted from informed consent and conducted in accordance with the Declaration of Helsinki and relevant regulations.</p>
<p>A total of 47 young patients diagnosed with PFO at Zibo Central Hospital (PFO group) between January 2022 and February 2024 were retrospectively enrolled (<xref ref-type="fig" rid="fig1">Figure 1</xref>).</p>
<fig position="float" id="fig1">
<label>Figure 1</label>
<caption>
<p>Flowchart of patient enrollment.</p>
</caption>
<graphic xlink:href="fneur-16-1737566-g001.tif" mimetype="image" mime-subtype="tiff">
<alt-text content-type="machine-generated">Flowchart depicting participant selection in a study. Initially, 245 participants aged 18&#x2013;55 were selected, diagnosed with PFO by TEE, and had brain MRIs and lab data collected. Migraine diagnosis followed ICHD-III criteria. Exclusions included those with hypertension, diabetes, brain diseases, substance abuse, neuropsychiatric or major physical diseases, atherosclerosis, severe heart disease risk, or poor MRI quality, narrowing to 47 final participants.</alt-text>
</graphic>
</fig>
<p>The inclusion criteria for the PFO group were as follows: (1) Diagnosis of PFO via transesophageal echocardiography (TEE); (2) Age between 18 and 55&#x202F;years (<xref ref-type="bibr" rid="ref13">13</xref>), irrespective of sex; (3) Completion of cranial MRI scanning; (4) Availability of laboratory data; (5) A documented history of migraines that aligns with the diagnostic criteria outlined in the International Classification of Headache Disorders, 3rd edition (ICHD-III) (<xref ref-type="bibr" rid="ref14">14</xref>). The exclusion criteria included: (1) A history of hypertension or diabetes mellitus; (2) A history of major cerebrovascular diseases, such as stroke, intracranial hemorrhage, brain tumors, multiple sclerosis, or significant traumatic brain injury; (3) A history of substance abuse, alcoholism, or dependence; (4) A history of neuropsychiatric disorders or a family history of such conditions; (5) A history of major systemic diseases, including malignancy, uremia, autoimmune diseases, or thyroid/parathyroid dysfunction; (6) Significant atherosclerosis, defined as stenosis of 50% or greater, as detected by CT angiography of the head and neck or color Doppler ultrasound; (7) Severe organic heart disease or other high-risk conditions for cardioembolism; (8) Poor-quality MRI images.</p>
<p>Healthy controls (HC group) were retrospectively selected from individuals who underwent brain MRI scanning during the same period as part of routine health examinations. The MRI scanning protocols for the HC group were matched with those of the PFO group to ensure consistency in the assessment of WMH. The control group was screened to adhere to the same exclusion criteria as the PFO group, ensuring the absence of significant cerebrovascular diseases and specified systemic conditions. Ultimately, 50 healthy controls, matched for age and sex, were included in the study.</p>
</sec>
<sec id="sec4">
<label>2.2</label>
<title>Laboratory test indicators</title>
<p>Laboratory test indicators assessed for patients in the PFO group encompassed brain natriuretic peptide, fibrinogen, C-reactive protein, mean platelet volume, homocysteine, lipoprotein(a), total cholesterol, fasting blood glucose, serum creatinine, serum uric acid, and serum urea. All laboratory indicators were collected within 7 days preceding the MRI examination.</p>
</sec>
<sec id="sec5">
<label>2.3</label>
<title>Color ultrasound data collection</title>
<p>A contrast transesophageal echocardiography (cTEE) procedure was conducted using a Philips EPIQ CVx (Philips Healthcare, MA, United States) by an experienced sonographer (W. Z., with 7 years of ultrasound diagnostic experience). The PFO diameter was measured using an electronic caliper, and the maximum opening of the PFO was recorded during the end-diastolic phase. Absolute contraindications included dysphagia, esophageal pathology, or recent surgery. Relative contraindications, such as esophageal varices or active upper gastrointestinal bleeding, necessitated a pre-procedural risk assessment (<xref ref-type="bibr" rid="ref15">15</xref>).</p>
<p>Patients were positioned in the left lateral decubitus orientation for the purpose of conducting contrast echocardiography. An agitated saline solution was administered via the left antecubital vein. The presence, timing, and grading of RLS were evaluated during both resting conditions and the Valsalva maneuver, as confirmed by TTE (Transthoracic Echocardiograph). The severity of RLS was classified based on the number of microbubbles detected in the left atrium during TTE: Grade 1 (minimal) was characterized by 1&#x2013;10 bubbles; Grade 2 (moderate) by 11&#x2013;25 bubbles; and Grade 3 by more than 25 bubbles or complete left atrial opacification (<xref ref-type="bibr" rid="ref10">10</xref>). RLS was further categorized as either persistent, occurring at rest without the Valsalva maneuver, or provoked, occurring exclusively during the Valsalva maneuver. Additionally, during TTE assessment, the presence of an Atrial Septal Aneurysm (ASA) was documented, defined as a protrusion of the septal base measuring &#x2265;10&#x202F;mm beyond the atrial septal plane or a total excursion of &#x2265;15&#x202F;mm throughout the cardiac cycle (<xref ref-type="bibr" rid="ref16">16</xref>).</p>
</sec>
<sec id="sec6">
<label>2.4</label>
<title>MRI data acquisition</title>
<p>All participants underwent brain magnetic resonance imaging (MRI) using a 3.0-Tesla clinical magnetic resonance scanner (MAGNETOM Skyra; Siemens, Erlangen, Germany) equipped with a 20-channel phased-array head surface coil. Routine MRI protocols included T1-weighted imaging (T1WI) fluid-attenuated inversion recovery (FLAIR) and T2-weighted imaging turbo spin-echo (T2WI TSE), and T2WI-FLAIR sequence scans, covering the whole brain. Scanning sequence parameters are presented in <xref rid="SM1" ref-type="supplementary-material">Supplementary Table S1</xref>.</p>
</sec>
<sec id="sec7">
<label>2.5</label>
<title>WMH grade</title>
<p>The location of WMH was categorized as either periventricular hyperintensity (PVH) or deep white matter hyperintensity (DWMH). The grading scale for each is typically from 0 to 3, based on visual rating scales like the Fazekas scale (<xref ref-type="bibr" rid="ref17">17</xref>). Grade 0: Absence of both PVH and DWMH. Grade 1: PVH presents as &#x201C;caps&#x201D; or pencil-thin lining; DWMH as punctate foci. Grade 2: PVH forms a smooth &#x201C;halo&#x201D;; DWMH shows beginning confluence of foci. Grade 3: PVH appears irregular and extends into deep white matter; DWMH appears as large confluent areas. Two neuroradiologists, one with 20&#x202F;years of experience (Q. S.) and another with 10&#x202F;years of experience (Y. L.), who were blinded to clinical information including age, sex, and group allocation, independently graded the WMH for all participants. Any discrepancies were resolved through consensus discussion.</p>
</sec>
<sec id="sec8">
<label>2.6</label>
<title>Headache impact test-6 (HIT-6), visual analog scale (VAS) and migraine disability assessment (MIDAS) scoring</title>
<p>Migraine severity was evaluated using the HIT-6, VAS, and MIDAS scores, which assesses headache-specific symptoms and the functional impairment associated with headache disorders. This evaluation was performed by a neurologist (Y. M.) with 10&#x202F;years of experience.</p>
</sec>
<sec id="sec9">
<label>2.7</label>
<title>Statistical analysis</title>
<p>Statistical analyses were carried out using the R software package<xref ref-type="fn" rid="fn0001"><sup>1</sup></xref> and the Statistical Package for Social Sciences version 27.0 (IBM Corp., Armonk, NY, United States). The inter-rater reliability for PVH and DWMH grading was assessed utilizing the Kappa statistic. Categorical data were presented as frequencies (percentages) and compared using chi-square tests. Continuous data were initially tested for normality. For data that did not follow a normal distribution, differences were represented as medians with interquartile ranges and analyzed using nonparametric statistical tests. Partial correlation analysis, adjusted for age and sex, was employed to investigate the associations between PFO diameter, WMH grade, RLS grade, RLS classification (persistent/provoked), presence of ASA, migraine severity (measured by HIT-6, VAS and MIDAS), and various laboratory indicators. Ordinal multinomial logistic regression analysis was conducted to assess the impact of PFO diameter and LS grade on WMH grade. <italic>p</italic>&#x202F;&#x003C;&#x202F;0.05 was considered indicative of statistical significance.</p>
</sec>
</sec>
<sec sec-type="results" id="sec10">
<label>3</label>
<title>Results</title>
<sec id="sec11">
<label>3.1</label>
<title>Clinical data and laboratory indicators</title>
<p>The study included a total of 47 patients with PFO (comprising 17 men and 30 women, aged 18&#x2013;55&#x202F;years). The HC group consisted of 50 participants (comprising 17 men and 33 women, aged 18&#x2013;55&#x202F;years). Comparative analysis between the two groups showed no significant differences in terms of sex and age (<italic>p</italic>&#x202F;=&#x202F;0.823 and 0.441, respectively). Provoked RLS was identified in 29 patients (61.7%), whereas persistent RLS was observed in 18 patients (38.3%). An ASA was detected in 9 patients with PFO, accounting for 19.1% of the cohort. Within the PFO group, the HIT-6 scores ranged from 36 to 78, with a median score of 44, the VAS scores ranged from 0 to 10, with a median score of 2.5, the MIDAS scores ranged from 0 to 540, with a median score of 37. The mean disease duration among migraine patients was 2.6&#x202F;years. The frequency of migraine attacks was 2.0 episodes per month (<xref ref-type="table" rid="tab1">Table 1</xref>). The laboratory data characteristics of the PFO group are detailed in <xref rid="SM1" ref-type="supplementary-material">Supplementary Table S2</xref>.</p>
<table-wrap position="float" id="tab1">
<label>Table 1</label>
<caption>
<p>Characteristics of PFO and HC groups.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="top">Characteristic</th>
<th align="center" valign="top" colspan="2">PFO group (<italic>n</italic> =&#x202F;47)</th>
<th align="center" valign="top">HC group (<italic>n</italic> =&#x202F;50)</th>
<th align="center" valign="top"><italic>&#x03C7;</italic><sup>2</sup>/<italic>T</italic></th>
<th align="center" valign="top"><italic>p</italic> value</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top">Sex (male)</td>
<td align="center" valign="top" colspan="2">17(36.2%)</td>
<td align="center" valign="top">17(34.0%)</td>
<td align="char" valign="top" char=".">0.05</td>
<td align="char" valign="top" char=".">0.823</td>
</tr>
<tr>
<td align="left" valign="top">Age (year)</td>
<td align="center" valign="top" colspan="2">37.00&#x202F;&#x00B1;&#x202F;20.00</td>
<td align="center" valign="top">38.00&#x202F;&#x00B1;&#x202F;13.00</td>
<td align="char" valign="top" char=".">&#x2212;0.774</td>
<td align="char" valign="top" char=".">0.441</td>
</tr>
<tr>
<td align="left" valign="top">PFO diameter (mm)</td>
<td align="center" valign="top" colspan="2">1.30(0.60)</td>
<td align="center" valign="top">&#x2013;</td>
<td/>
<td/>
</tr>
<tr>
<td align="left" valign="top" rowspan="3">RLS</td>
<td align="left" valign="top">Grade 1</td>
<td align="char" valign="top" char="(">3(6.4%)</td>
<td align="center" valign="top">&#x2013;</td>
<td/>
<td/>
</tr>
<tr>
<td align="left" valign="top">Grade 2</td>
<td align="char" valign="top" char="(">11(23.4%)</td>
<td align="center" valign="top">&#x2013;</td>
<td/>
<td/>
</tr>
<tr>
<td align="left" valign="top">Grade 3</td>
<td align="char" valign="top" char="(">33(70.2%)</td>
<td align="center" valign="top">&#x2013;</td>
<td/>
<td/>
</tr>
<tr>
<td align="left" valign="top">RLS type (provocative)</td>
<td align="center" valign="top" colspan="2">29(61.7%)</td>
<td align="center" valign="top">&#x2013;</td>
<td/>
<td/>
</tr>
<tr>
<td align="left" valign="top">ASA</td>
<td align="center" valign="top" colspan="2">9(19.1%)</td>
<td align="center" valign="top">&#x2013;</td>
<td/>
<td/>
</tr>
<tr>
<td align="left" valign="top">HTI-6</td>
<td align="center" valign="top" colspan="2">44.0(16.0)</td>
<td align="center" valign="top">&#x2013;</td>
<td/>
<td/>
</tr>
<tr>
<td align="left" valign="top">MIDAS</td>
<td align="center" valign="top" colspan="2">37(80.0)</td>
<td align="center" valign="top">&#x2013;</td>
<td/>
<td/>
</tr>
<tr>
<td align="left" valign="top">VAS</td>
<td align="center" valign="top" colspan="2">2.5(6.0)</td>
<td align="center" valign="top">&#x2013;</td>
<td/>
<td/>
</tr>
<tr>
<td align="left" valign="top">Mean disease duration (year)</td>
<td align="center" valign="top" colspan="2">2.6(9.0)</td>
<td align="center" valign="top">&#x2013;</td>
<td/>
<td/>
</tr>
<tr>
<td align="left" valign="top">Attack frequency (episodes/month)</td>
<td align="center" valign="top" colspan="2">2.0(4.0)</td>
<td align="center" valign="top">&#x2013;</td>
<td/>
<td/>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p>HC, healthy control; PFO, patent foramen ovale; RLS, right-to-left shunt; ASA, atrial septal aneurysm; HTI-6, headache impact test-6; MIDAS, migraine disability assessment; VAS, visual analog scale.</p>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="sec12">
<label>3.2</label>
<title>WMH grade consistency test</title>
<p>The Kappa test results indicated excellent inter-rater reliability in the grading of WMH between the two neuroradiologist, with Kappa coefficients of 0.983 for PVH and 0.910 for DWMH, both with <italic>p</italic>&#x202F;&#x003C;&#x202F;0.001.</p>
</sec>
<sec id="sec13">
<label>3.3</label>
<title>WMH grade group comparison</title>
<p>Comparative analysis of WMH grades between the PFO and HC groups revealed significantly higher grades for both PVH and DWMH in the PFO group (<italic>p</italic>&#x202F;&#x003C;&#x202F;0.001 for both), as shown in <xref ref-type="table" rid="tab2">Table 2</xref> and <xref ref-type="fig" rid="fig2">Figure 2</xref>. Representative images of WMH were shown in <xref ref-type="fig" rid="fig3">Figure 3</xref>.</p>
<table-wrap position="float" id="tab2">
<label>Table 2</label>
<caption>
<p>Comparison of WMH grades between PFO and HC groups.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th>Type</th>
<th>Grade</th>
<th align="center" valign="top">PFO group (<italic>n</italic> =&#x202F;47)</th>
<th align="center" valign="top">HC group (<italic>n</italic> =&#x202F;50)</th>
<th align="center" valign="top">
<italic>&#x03C7;</italic>
<sup>2</sup>
</th>
<th align="center" valign="top"><italic>p-</italic>value</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top" rowspan="4">PVH</td>
<td align="left" valign="top">0</td>
<td align="char" valign="top" char="(">7(14.9%)</td>
<td align="center" valign="top">33(66.0%)</td>
<td align="char" valign="top" char="." rowspan="4">30.967</td>
<td align="char" valign="top" char="." rowspan="4">&#x003C;0.001</td>
</tr>
<tr>
<td align="left" valign="top">1</td>
<td align="char" valign="top" char="(">29(61.7%)</td>
<td align="center" valign="top">17(34.0%)</td>
</tr>
<tr>
<td align="left" valign="top">2</td>
<td align="char" valign="top" char="(">9(19.1%)</td>
<td align="center" valign="top">0</td>
</tr>
<tr>
<td align="left" valign="top">3</td>
<td align="char" valign="top" char="(">2(4.3%)</td>
<td align="center" valign="top">0</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="4">DWMH</td>
<td align="left" valign="top">0</td>
<td align="char" valign="top" char="(">16(34.0%)</td>
<td align="center" valign="top">41(82.0%)</td>
<td align="char" valign="top" char="." rowspan="4">26.069</td>
<td align="char" valign="top" char="." rowspan="4">&#x003C;0.001</td>
</tr>
<tr>
<td align="left" valign="top">1</td>
<td align="char" valign="top" char="(">20(42.6%)</td>
<td align="center" valign="top">9(18.0%)</td>
</tr>
<tr>
<td align="left" valign="top">2</td>
<td align="char" valign="top" char="(">4(8.5%)</td>
<td align="center" valign="top">0</td>
</tr>
<tr>
<td align="left" valign="top">3</td>
<td align="char" valign="top" char="(">7(14.9%)</td>
<td align="center" valign="top">0</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p>DWMH, deep white matter hyperintensity; PVH, periventricular hyperintensity; WMH, white matter hyperintensity.</p>
</table-wrap-foot>
</table-wrap>
<fig position="float" id="fig2">
<label>Figure 2</label>
<caption>
<p>Column diagram of WMH grade between PFO and HC groups. It shows the distribution of PVH and DWMH grade in the PFO and the HC groups. DWMH, deep white matter hyperintensity; HC, healthy control; PFO, patent foramen ovale; PVH, periventricular hyperintensity.</p>
</caption>
<graphic xlink:href="fneur-16-1737566-g002.tif" mimetype="image" mime-subtype="tiff">
<alt-text content-type="machine-generated">Stacked bar chart comparing grades across four categories: PFO-PVH, PFO-DWMH, HC-PVH, and HC-DWMH. Each category is divided into Grade 0 (green), Grade 1 (purple), Grade 2 (yellow), and Grade 3 (blue). PFO-PVH has significant Grade 1 presence (61.70%), PFO-DWMH has a mix with notable Grade 0 (34.00%), HC-PVH is mostly Grade 0 (66.00%), and HC-DWMH is predominantly Grade 0 (82.00%). Statistical significance indicated with P &#x003C; 0.05.</alt-text>
</graphic>
</fig>
<fig position="float" id="fig3">
<label>Figure 3</label>
<caption>
<p>Representative images of WMH. FLAIR image of patient 1 with PFO: female, 50&#x202F;years old, migraine, PFO diameter 3.3&#x202F;mm, PVH Grade 2 <bold>(A)</bold> and DWMH Grade 3 <bold>(B)</bold>. FLAIR image of patient 2 with PFO: male, 47&#x202F;years old, without migraine, PFO diameter 2.0&#x202F;mm, PVH Grade 2 <bold>(C)</bold> and DWMH Grade 1 <bold>(D)</bold>. FLAIR image of HC: female, 49&#x202F;years old, PVH Grade 1 <bold>(E)</bold> and DWMH Grade 0 <bold>(F)</bold>. WMH, white matter hyperintensity; DWMH, deep white matter hyperintensity; HC, healthy control; PFO, patent foramen ovale; PVH, periventricular hyperintensity.</p>
</caption>
<graphic xlink:href="fneur-16-1737566-g003.tif" mimetype="image" mime-subtype="tiff">
<alt-text content-type="machine-generated">MRI brain scans display: A and B show PFO with migraine and high white matter hyperintensity (WMH) burden, marked by arrows. C and D illustrate PFO without migraine, with highlighted areas. E and F represent a healthy control, with minimal WMH.</alt-text>
</graphic>
</fig>
</sec>
<sec id="sec14">
<label>3.4</label>
<title>Correlation of PFO diameter with laboratory indicators, HIT-6 score, VAS score, MIDAS score, RLS grade and WMH grade</title>
<p>Partial correlation analysis, controlling for sex and age, demonstrated a positive correlation between the PFO diameter and PVH (<italic>r</italic>&#x202F;=&#x202F;0.539, <italic>p</italic>&#x202F;&#x003C;&#x202F;0.001), DWMH (<italic>r</italic>&#x202F;=&#x202F;0.550, <italic>p</italic>&#x202F;&#x003C;&#x202F;0.001), HIT-6 score (<italic>r</italic>&#x202F;=&#x202F;0.751, <italic>p</italic>&#x202F;&#x003C;&#x202F;0.001), VAS score (<italic>r</italic>&#x202F;=&#x202F;0.577, <italic>p</italic>&#x202F;&#x003C;&#x202F;0.001), MIDAS score (<italic>r</italic>&#x202F;=&#x202F;0.751, <italic>p</italic>&#x202F;&#x003C;&#x202F;0.001), and RLS grades (<italic>r</italic>&#x202F;=&#x202F;0.296, <italic>p</italic>&#x202F;=&#x202F;0.048). Furthermore, PVH (<italic>r</italic>&#x202F;=&#x202F;0.430, <italic>p</italic>&#x202F;=&#x202F;0.003), DWMH (<italic>r</italic>&#x202F;=&#x202F;0.365, <italic>p</italic>&#x202F;=&#x202F;0.014), VAS score (<italic>r</italic>&#x202F;=&#x202F;0.480, <italic>p</italic>&#x202F;=&#x202F;0.001), MIDAS score (<italic>r</italic>&#x202F;=&#x202F;0.453, <italic>p</italic>&#x202F;=&#x202F;0.002), and HIT-6 score (<italic>r</italic>&#x202F;=&#x202F;0.452, <italic>p</italic>&#x202F;=&#x202F;0.002) were positively correlated with RLS grade. The PVH grade was found to have a positive correlation with HIT-6 score (<italic>r</italic>&#x202F;=&#x202F;0.643, <italic>p</italic>&#x202F;&#x003C;&#x202F;0.001), VAS score (<italic>r</italic>&#x202F;=&#x202F;0.764, <italic>p</italic>&#x202F;&#x003C;&#x202F;0.001), and MIDAS score (<italic>r</italic>&#x202F;=&#x202F;0.654, <italic>p</italic>&#x202F;&#x003C;&#x202F;0.001). The DWMH grade was found to have a positive correlation with HIT-6 score (<italic>r</italic>&#x202F;=&#x202F;0.712, <italic>p</italic>&#x202F;&#x003C;&#x202F;0.001), VAS score (<italic>r</italic>&#x202F;=&#x202F;0.817, <italic>p</italic>&#x202F;&#x003C;&#x202F;0.001), and MIDAS score (<italic>r</italic>&#x202F;=&#x202F;0.675, <italic>p</italic>&#x202F;&#x003C;&#x202F;0.001).</p>
<p><xref ref-type="fig" rid="fig4">Figure 4</xref> presents a heatmap illustrating the correlations among PFO diameter, RLS grade, HIT-6 scores, VAS scores, MIDAS scores, laboratory indicators, and WMH grades.</p>
<fig position="float" id="fig4">
<label>Figure 4</label>
<caption>
<p>Heat map depicting the correlation among PFO diameters, WMH grades, RLS grade, HTI-6 scores, VAS scores, MIDAS scores, and laboratory indexes. The color bar on the right and the symbols in the figure display correlations. BNP, brain natriuretic peptide; FIB, fibrinogen; Cr, serum creatinine; CRP, c-reactive protein; DWMH, deep white matter hyperintensity; FBG, fasting blood glucose; HCY, homocysteine; Lp_a, lipoprotein(a); MPV, mean platelet volume; PFO, patent foramen ovale; PVH, periventricular hyperintensity; RLS, right-to-left shunt; TC, total cholesterol; UA, serum uric acid; UU, serum urea; HTI-6, headache impact test-6; MIDAS, migraine disability assessment; VAS, Visual Analogue Scale. <sup>&#x002A;</sup><italic>p</italic>&#x202F;&#x003C;&#x202F;0.05, <sup>&#x002A;&#x002A;</sup><italic>p</italic>&#x202F;&#x003C;&#x202F;0.01, and <sup>&#x002A;&#x002A;&#x002A;</sup><italic>p</italic>&#x202F;&#x003C;&#x202F;0.001.</p>
</caption>
<graphic xlink:href="fneur-16-1737566-g004.tif" mimetype="image" mime-subtype="tiff">
<alt-text content-type="machine-generated">Correlation matrix heatmap displaying relationships between various medical and biochemical parameters. Darker red indicates a stronger positive correlation, while darker blue indicates a stronger negative correlation. Key parameters include RLS grade, PVH, DWMH, PFO diameter, MIDAS, and HIT-6 among others. A color scale bar on the right ranges from negative one to one.</alt-text>
</graphic>
</fig>
<p>However, neither the type of RLS (provoked vs. persistent) nor the presence of ASA exhibited statistically significant correlations with WMH grades, HIT-6 scores, VAS scores, or MIDAS scores (<italic>p</italic>&#x202F;&#x003E;&#x202F;0.05).</p>
</sec>
<sec id="sec15">
<label>3.5</label>
<title>Ordinal multinomial logistic regression analysis of the impact of PFO diameter and RLS grade on PVH and DWMH grades</title>
<p>The ordinal multinomial logistic regression analysis assessing the impact of PFO diameter on PVH and DWMH grades indicated that PFO diameter serves as an independent influencing factor for both PVH and DWMH grades (<italic>p</italic>&#x202F;&#x003C;&#x202F;0.001) (<xref ref-type="table" rid="tab3">Table 3</xref>).</p>
<table-wrap position="float" id="tab3">
<label>Table 3</label>
<caption>
<p>Ordered multiple logistic regression analysis of the effect of PFO diameter on PVH and DWMH grades.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="top" rowspan="2">Variable</th>
<th align="center" valign="top" rowspan="2">
<italic>B</italic>
</th>
<th align="center" valign="top" colspan="2">95% CI</th>
<th align="center" valign="top" rowspan="2"><italic>p-</italic>value</th>
</tr>
<tr>
<th align="center" valign="top">Lower limit</th>
<th align="center" valign="top">Upper limit</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top">PVH</td>
<td align="char" valign="middle" char=".">2.247</td>
<td align="char" valign="middle" char=".">1.031</td>
<td align="char" valign="middle" char=".">3.464</td>
<td align="char" valign="top" char=".">&#x003C;0.001</td>
</tr>
<tr>
<td align="left" valign="top">DWMH</td>
<td align="char" valign="middle" char=".">1.841</td>
<td align="char" valign="middle" char=".">0.749</td>
<td align="char" valign="middle" char=".">2.933</td>
<td align="char" valign="top" char=".">&#x003C;0.001</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p>CI, confidential interval; DWMH, deep white matter hyperintensity; PFO, patent foramen ovale; PVH, periventricular hyperintensity.</p>
</table-wrap-foot>
</table-wrap>
</sec>
</sec>
<sec sec-type="discussion" id="sec16">
<label>4</label>
<title>Discussion</title>
<p>This study concentrated on young patients with PFO, identifying a significantly increased burden of WMH. Subsequent analysis demonstrated that the PFO diameter was strongly correlated with the severity of both PVH and DWMH, as well as with the grade of RLS. Notably, multivariate analysis confirmed that the PFO diameter serves as an independent risk factor influencing the severity of PVH and DWMH.</p>
<p>The findings suggest that PFO is a risk factor not only for stroke but also for an extensive WMH burden in the brain (<xref ref-type="bibr" rid="ref6">6</xref>). However, previous studies have not consistently established an association between PFO and WMH. This inconsistency may be attributed to the greater impact of PFO on stroke risk in younger patients, whereas studies such as that by Di Tullio et al. (<xref ref-type="bibr" rid="ref18">18</xref>) involved participants with a relatively high mean age (68.4&#x202F;&#x00B1;&#x202F;9.4&#x202F;years). Advanced age itself is a significant risk factor for cerebrovascular disease and WMH, and its substantial confounding effect may obscure the relatively weaker independent contribution of PFO. In this study, we focused on young individuals to minimize age-related confounding factors in stroke risk and to investigate the association between PFO and the severity of WMH.</p>
<p>The PFO is recognized as a risk factor for paradoxical embolism and stroke, serving as an anatomical conduit for emboli to reach the brain and potentially cause cerebrovascular events (<xref ref-type="bibr" rid="ref19">19</xref>, <xref ref-type="bibr" rid="ref20">20</xref>). WMH is a prevalent neuroimaging marker indicative of brain health (<xref ref-type="bibr" rid="ref21">21</xref>). The Fazekas scoring system categorizes WMH into two regions: PVH and DWMH, assessing the severity of each separately. PVH is characterized by gliosis, myelin pallor, and demyelination, whereas DWMH is more heterogeneous, with greater axonal loss, vacuolation, and arteriolosclerosis (<xref ref-type="bibr" rid="ref22">22</xref>). Prior research has associated PFO with white matter lesions (<xref ref-type="bibr" rid="ref23">23</xref>, <xref ref-type="bibr" rid="ref24">24</xref>), primarily located in the deep white matter and appearing punctate (<xref ref-type="bibr" rid="ref25">25</xref>). Our findings demonstrate a positive correlation between increased PVH and DWMH burden and the PFO diameter. Regression analysis revealed that the PFO diameter is an independent predictor of both PVH and DWMH grades. This suggests that patients with larger PFO diameters may experience increased microembolic entry into the arterial circulation, impacting the cerebral microvasculature. Consequently, patients with larger PFO diameters demonstrate increased cerebral gliosis, myelin pallor, demyelination, axonal loss, vacuolation, and arteriolosclerosis.</p>
<p>This study also identified a positive correlation between RLS and both WMH burden and migraine severity, aligning with previous research findings (<xref ref-type="bibr" rid="ref3">3</xref>, <xref ref-type="bibr" rid="ref12">12</xref>). RLS has been implicated as a potential contributing factor for stroke and migraine with aura in the presence of PFO (<xref ref-type="bibr" rid="ref26">26</xref>). As the RLS grade escalates, the passage of small microemboli or vasoactive substances, such as serotonin, through the PFO also increases (<xref ref-type="bibr" rid="ref27">27</xref>). These factors may precipitate migraines via cortical spreading depression (CSD) and induce cerebral white matter microvascular damage and an elevated WMH burden through direct or indirect CSD-related ischemia or neuroinflammation (<xref ref-type="bibr" rid="ref28">28</xref>, <xref ref-type="bibr" rid="ref29">29</xref>). This suggests that the observed increase in WMH burden in young PFO patients may involve overlapping or interacting pathophysiological processes associated with both RLS and migraine.</p>
<p>The relationship between migraine and WMH has garnered substantial attention, with WMH being considered a marker of chronic migraine (<xref ref-type="bibr" rid="ref7">7</xref>), potentially affecting cognitive function and other neurological outcomes. The migraine severity assessment indicators in this study, including the VAS, HIT-6, and MIDAS scores, demonstrated statistically significant correlations with the grades of PVH and DWMH. A substantial of neuroimaging studies has demonstrated that migraine patients are more likely to exhibit WMH compared to HC (<xref ref-type="bibr" rid="ref29">29</xref>, <xref ref-type="bibr" rid="ref30">30</xref>). And a significant proportion of migraine patients (63.9%) exhibit WMH on T2WI and T2WI-FLAIR (<xref ref-type="bibr" rid="ref26">26</xref>, <xref ref-type="bibr" rid="ref31">31</xref>). The pathophysiological mechanisms underlying WMH in migraine have not been fully elucidated. Possible mechanisms include: brain injury induced by metalloproteinases activated during cortical spreading depolarization, ischemic microvascular dysfunction with subsequent regional hypoperfusion, microembolization, hypercoagulable states, and endothelial dysfunction (<xref ref-type="bibr" rid="ref29">29</xref>). Preclinical studies have demonstrated that microemboli, such as air, polystyrene microspheres, and cholesterol particles, can induce CSD (<xref ref-type="bibr" rid="ref32">32</xref>). Smaller emboli are associated with rapid and transient CSD, accompanied by a significant reduction in cerebral blood flow (CBF) (<xref ref-type="bibr" rid="ref33">33</xref>). This mechanism, wherein microemboli induce CSD that may progress to ischemic events, offers a biological rationale for the observed association between migraine and ischemic stroke in patients with PFO (<xref ref-type="bibr" rid="ref33">33</xref>, <xref ref-type="bibr" rid="ref34">34</xref>).</p>
<p>This study acknowledges several limitations that suggest avenues for future research. Firstly, the small sample size and reliance on a single-source origin necessitate validation in larger cohorts. Secondly, since TTE is an invasive procedure and was not performed on the HC group, along with missing blood biomarker information, may introduce potential selection bias. Thirdly, the manual classification of WMH based on two-dimensional (2D) imaging data constrains the accuracy of quantifying WMH burden in patients with PFO. Future studies should incorporate artificial intelligence methodologies combined with three-dimensional (3D) imaging to achieve more precise volumetric measurements and standardized quantification. Lastly, as this was a retrospective study, data on the presence of migraine aura were unavailable. These data will be systematically collected and analyzed in future prospective studies.</p>
</sec>
<sec sec-type="conclusions" id="sec17">
<label>5</label>
<title>Conclusion</title>
<p>In conclusion, young patients with PFO exhibit a higher burden of WMH, and the PFO diameter emerges as an independent risk factor for the severity of WMH. These findings suggest that PFO may contribute to the development of WMH in young individuals, potentially through mechanisms involving paradoxical embolism and chronic cerebral hypoperfusion. In young patients with PFO and migraine, monitoring WMH burden via neuroimaging may provide insights for future personalized management strategies.</p>
</sec>
</body>
<back>
<sec sec-type="data-availability" id="sec18">
<title>Data availability statement</title>
<p>The original contributions presented in the study are included in the article/<xref rid="SM1" ref-type="supplementary-material">Supplementary material</xref>, further inquiries can be directed to the corresponding authors.</p>
</sec>
<sec sec-type="ethics-statement" id="sec19">
<title>Ethics statement</title>
<p>The studies involving humans were approved by the Ethics Committee of Zibo Central Hospital (Approval number: 2024219). The studies were conducted in accordance with the local legislation and institutional requirements. Written informed consent to participate in this study was provided by the patients/participants or patients/participants&#x2019; legal guardian/next of kin.</p>
</sec>
<sec sec-type="author-contributions" id="sec20">
<title>Author contributions</title>
<p>YLi: Conceptualization, Data curation, Methodology, Writing &#x2013; original draft. YLiu: Conceptualization, Data curation, Funding acquisition, Methodology, Writing &#x2013; original draft. JC: Writing &#x2013; review &#x0026; editing. QS: Formal analysis, Supervision, Writing &#x2013; original draft. WZhe: Methodology, Writing &#x2013; original draft. JL: Data curation, Writing &#x2013; original draft. XS: Data curation, Writing &#x2013; original draft. JX: Resources, Software, Writing &#x2013; original draft. WZha: Methodology, Writing &#x2013; original draft. YM: Methodology, Writing &#x2013; original draft. BL: Conceptualization, Writing &#x2013; review &#x0026; editing. XL: Conceptualization, Writing &#x2013; review &#x0026; editing.</p>
</sec>
<sec sec-type="COI-statement" id="sec21">
<title>Conflict of interest</title>
<p>JX was employed by Siemens Healthineers Ltd.</p>
<p>The remaining author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="ai-statement" id="sec22">
<title>Generative AI statement</title>
<p>The author(s) declared that Generative AI was not used in the creation of this manuscript.</p>
<p>Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.</p>
</sec>
<sec sec-type="disclaimer" id="sec23">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<sec sec-type="supplementary-material" id="sec24">
<title>Supplementary material</title>
<p>The Supplementary material for this article can be found online at: <ext-link xlink:href="https://www.frontiersin.org/articles/10.3389/fneur.2025.1737566/full#supplementary-material" ext-link-type="uri">https://www.frontiersin.org/articles/10.3389/fneur.2025.1737566/full#supplementary-material</ext-link></p>
<supplementary-material xlink:href="Table_1.docx" id="SM1" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</sec>
<ref-list>
<title>References</title>
<ref id="ref1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mac Grory</surname><given-names>B</given-names></name> <name><surname>Ohman</surname><given-names>EM</given-names></name> <name><surname>Feng</surname><given-names>W</given-names></name> <name><surname>Xian</surname><given-names>Y</given-names></name> <name><surname>Yaghi</surname><given-names>S</given-names></name> <name><surname>Kamel</surname><given-names>H</given-names></name> <etal/></person-group>. <article-title>Advances in the management of cardioembolic stroke associated with patent foramen ovale</article-title>. <source>BMJ</source>. (<year>2022</year>) <volume>376</volume>:<fpage>e063161</fpage>. doi: <pub-id pub-id-type="doi">10.1136/bmj-2020-063161</pub-id>, <pub-id pub-id-type="pmid">35140114</pub-id></mixed-citation></ref>
<ref id="ref2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lechat</surname><given-names>P</given-names></name> <name><surname>Mas</surname><given-names>JL</given-names></name> <name><surname>Lascault</surname><given-names>G</given-names></name> <name><surname>Loron</surname><given-names>PH</given-names></name> <name><surname>Theard</surname><given-names>M</given-names></name> <name><surname>Klimczac</surname><given-names>M</given-names></name> <etal/></person-group>. <article-title>Prevalence of patent foramen ovale in patients with stroke</article-title>. <source>N Engl J Med</source>. (<year>1988</year>) <volume>318</volume>:<fpage>1148</fpage>&#x2013;<lpage>52</lpage>. doi: <pub-id pub-id-type="doi">10.1056/NEJM198805053181802</pub-id>, <pub-id pub-id-type="pmid">3362165</pub-id></mixed-citation></ref>
<ref id="ref3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>XH</given-names></name> <name><surname>Wang</surname><given-names>SB</given-names></name> <name><surname>Tian</surname><given-names>Q</given-names></name> <name><surname>Zhong</surname><given-names>C</given-names></name> <name><surname>Zhang</surname><given-names>GL</given-names></name> <name><surname>Li</surname><given-names>YJ</given-names></name> <etal/></person-group>. <article-title>Right-to-left shunt and subclinical ischemic brain lesions in Chinese migraineurs: a multicentre MRI study</article-title>. <source>BMC Neurol</source>. (<year>2018</year>) <volume>18</volume>:<fpage>18</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12883-018-1022-7</pub-id>, <pub-id pub-id-type="pmid">29444659</pub-id></mixed-citation></ref>
<ref id="ref4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duering</surname><given-names>M</given-names></name> <name><surname>Biessels</surname><given-names>GJ</given-names></name> <name><surname>Brodtmann</surname><given-names>A</given-names></name> <name><surname>Chen</surname><given-names>C</given-names></name> <name><surname>Cordonnier</surname><given-names>C</given-names></name> <name><surname>de Leeuw</surname><given-names>FE</given-names></name> <etal/></person-group>. <article-title>Neuroimaging standards for research into small vessel disease-advances since 2013</article-title>. <source>Lancet Neurol</source>. (<year>2023</year>) <volume>22</volume>:<fpage>602</fpage>&#x2013;<lpage>18</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S1474-4422(23)00131-X</pub-id>, <pub-id pub-id-type="pmid">37236211</pub-id></mixed-citation></ref>
<ref id="ref5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuller</surname><given-names>LH</given-names></name> <name><surname>Longstreth</surname><given-names>WT</given-names> <suffix>Jr</suffix></name> <name><surname>Arnold</surname><given-names>AM</given-names></name> <name><surname>Bernick</surname><given-names>C</given-names></name> <name><surname>Bryan</surname><given-names>RN</given-names></name> <name><surname>Beauchamp</surname><given-names>NJ</given-names></name></person-group>. <article-title>White matter hyperintensity on cranial magnetic resonance imaging: a predictor of stroke</article-title>. <source>Stroke</source>. (<year>2004</year>) <volume>35</volume>:<fpage>1821</fpage>&#x2013;<lpage>5</lpage>. doi: <pub-id pub-id-type="doi">10.1161/01.STR.0000132193.35955.69</pub-id>, <pub-id pub-id-type="pmid">15178824</pub-id></mixed-citation></ref>
<ref id="ref6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Badea</surname><given-names>R&#x0218;</given-names></name> <name><surname>Mih&#x0103;il&#x0103;-B&#x00E2;ldea</surname><given-names>S</given-names></name> <name><surname>Ribigan</surname><given-names>A</given-names></name> <name><surname>Negril&#x0103;</surname><given-names>A</given-names></name> <name><surname>Grecu</surname><given-names>N</given-names></name> <name><surname>Marinescu</surname><given-names>AN</given-names></name> <etal/></person-group>. <article-title>PFO-spectrum disorder: two different cerebrovascular diseases in patients with PFO as detected by AI brain imaging software</article-title>. <source>Front Neurol</source>. (<year>2024</year>) <volume>15</volume>:<fpage>1357348</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fneur.2024.1357348</pub-id>, <pub-id pub-id-type="pmid">38440117</pub-id></mixed-citation></ref>
<ref id="ref7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abdalla</surname><given-names>K</given-names></name> <name><surname>Alawneh</surname><given-names>KZ</given-names></name> <name><surname>Al-Bdour</surname><given-names>M</given-names></name> <name><surname>Abu-Salih</surname><given-names>AQ</given-names></name></person-group>. <article-title>Migraine and MRI: uncovering potential associations</article-title>. <source>Head Face Med</source>. (<year>2025</year>) <volume>21</volume>:<fpage>6</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s13005-024-00478-2</pub-id>, <pub-id pub-id-type="pmid">39955604</pub-id></mixed-citation></ref>
<ref id="ref8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huo</surname><given-names>J</given-names></name> <name><surname>Zhang</surname><given-names>G</given-names></name> <name><surname>Wang</surname><given-names>W</given-names></name> <name><surname>Cao</surname><given-names>W</given-names></name> <name><surname>Wan</surname><given-names>M</given-names></name> <name><surname>Huang</surname><given-names>T</given-names></name> <etal/></person-group>. <article-title>Migraine and white matter lesions: a mendelian randomization study</article-title>. <source>Sci Rep</source>. (<year>2023</year>) <volume>13</volume>:<fpage>10984</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41598-023-38182-x</pub-id>, <pub-id pub-id-type="pmid">37415088</pub-id></mixed-citation></ref>
<ref id="ref9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iwasaki</surname><given-names>A</given-names></name> <name><surname>Suzuki</surname><given-names>K</given-names></name> <name><surname>Takekawa</surname><given-names>H</given-names></name> <name><surname>Takashima</surname><given-names>R</given-names></name> <name><surname>Suzuki</surname><given-names>A</given-names></name> <name><surname>Suzuki</surname><given-names>S</given-names></name> <etal/></person-group>. <article-title>The relationship between right-to-left shunt and brain white matter lesions in Japanese patients with migraine: a single center study</article-title>. <source>J Headache Pain</source>. (<year>2017</year>) <volume>18</volume>:<fpage>3</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s10194-016-0714-x</pub-id>, <pub-id pub-id-type="pmid">28063107</pub-id></mixed-citation></ref>
<ref id="ref10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gaspardone</surname><given-names>A</given-names></name> <name><surname>Sgueglia</surname><given-names>GA</given-names></name> <name><surname>De Santis</surname><given-names>A</given-names></name> <name><surname>D'Ascoli</surname><given-names>E</given-names></name> <name><surname>Iamele</surname><given-names>M</given-names></name> <name><surname>Piccioni</surname><given-names>F</given-names></name> <etal/></person-group>. <article-title>Predictors of residual right-to-left shunt after percutaneous suture-mediated patent fossa ovalis closure</article-title>. <source>JACC Cardiovasc Interv</source>. (<year>2020</year>) <volume>13</volume>:<fpage>2112</fpage>&#x2013;<lpage>20</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jcin.2020.06.004</pub-id>, <pub-id pub-id-type="pmid">32972572</pub-id></mixed-citation></ref>
<ref id="ref11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>X</given-names></name> <name><surname>Zhang</surname><given-names>Y</given-names></name> <name><surname>Xie</surname><given-names>H</given-names></name> <name><surname>Zeng</surname><given-names>H</given-names></name> <name><surname>Sun</surname><given-names>J</given-names></name> <name><surname>Su</surname><given-names>L</given-names></name> <etal/></person-group>. <article-title>Change in patent foramen ovale height is associated with cryptogenic stroke and the construction of a morphology-based scoring system</article-title>. <source>Front Cardiovasc Med</source>. (<year>2022</year>) <volume>9</volume>:<fpage>1010947</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fcvm.2022.1010947</pub-id>, <pub-id pub-id-type="pmid">36518683</pub-id></mixed-citation></ref>
<ref id="ref12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>H</given-names></name> <name><surname>Zhang</surname><given-names>S</given-names></name> <name><surname>Xie</surname><given-names>Q</given-names></name> <name><surname>Zhu</surname><given-names>Z</given-names></name> <name><surname>Li</surname><given-names>L</given-names></name> <name><surname>Zhao</surname><given-names>H</given-names></name></person-group>. <article-title>Compromised cerebrovascular reactivity related to presence of white matter hyperintensities in cryptogenic stroke with right-to-left shunts</article-title>. <source>J Stroke Cerebrovasc Dis</source>. (<year>2025</year>) <volume>34</volume>:<fpage>108223</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jstrokecerebrovasdis.2025.108223</pub-id>, <pub-id pub-id-type="pmid">39778666</pub-id></mixed-citation></ref>
<ref id="ref13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tromp</surname><given-names>J</given-names></name> <name><surname>Paniagua</surname><given-names>SMA</given-names></name> <name><surname>Lau</surname><given-names>ES</given-names></name> <name><surname>Allen</surname><given-names>NB</given-names></name> <name><surname>Blaha</surname><given-names>MJ</given-names></name> <name><surname>Gansevoort</surname><given-names>RT</given-names></name> <etal/></person-group>. <article-title>Age dependent associations of risk factors with heart failure: pooled population based cohort study</article-title>. <source>BMJ</source>. (<year>2021</year>) <volume>372</volume>:<fpage>n461</fpage>. doi: <pub-id pub-id-type="doi">10.1136/bmj.n461</pub-id>, <pub-id pub-id-type="pmid">33758001</pub-id></mixed-citation></ref>
<ref id="ref14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olesen</surname><given-names>J</given-names></name></person-group>. <article-title>The international classification of headache disorders: history and future perspectives</article-title>. <source>Cephalalgia</source>. (<year>2024</year>) <volume>44</volume>:<fpage>3331024231214731</fpage>. doi: <pub-id pub-id-type="doi">10.1177/03331024231214731</pub-id>, <pub-id pub-id-type="pmid">38166472</pub-id></mixed-citation></ref>
<ref id="ref15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khandheria</surname><given-names>BK</given-names></name> <name><surname>Seward</surname><given-names>JB</given-names></name> <name><surname>Tajik</surname><given-names>AJ</given-names></name></person-group>. <article-title>Transesophageal echocardiography</article-title>. <source>Mayo Clin Proc</source>. (<year>1994</year>) <volume>69</volume>:<fpage>856</fpage>&#x2013;<lpage>63</lpage>. doi: <pub-id pub-id-type="doi">10.1016/s0025-6196(12)61788-1</pub-id>, <pub-id pub-id-type="pmid">8065188</pub-id></mixed-citation></ref>
<ref id="ref16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Niiyama</surname><given-names>S</given-names></name> <name><surname>Ueno</surname><given-names>Y</given-names></name> <name><surname>Kurita</surname><given-names>N</given-names></name> <name><surname>Nakajima</surname><given-names>S</given-names></name> <name><surname>Kijima</surname><given-names>C</given-names></name> <name><surname>Hira</surname><given-names>K</given-names></name> <etal/></person-group>. <article-title>White matter lesions as a prognostic marker of recurrence in cryptogenic stroke with high-risk patent foramen ovale</article-title>. <source>J Stroke Cerebrovasc Dis</source>. (<year>2024</year>) <volume>33</volume>:<fpage>108048</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jstrokecerebrovasdis.2024.108048</pub-id>, <pub-id pub-id-type="pmid">39476743</pub-id></mixed-citation></ref>
<ref id="ref17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>WQ</given-names></name> <name><surname>Lin</surname><given-names>Q</given-names></name> <name><surname>Tzeng</surname><given-names>CM</given-names></name></person-group>. <article-title>Leukoaraiosis: epidemiology, imaging, risk factors, and management of age-related cerebral white matter Hyperintensities</article-title>. <source>J Stroke</source>. (<year>2024</year>) <volume>26</volume>:<fpage>131</fpage>&#x2013;<lpage>63</lpage>. doi: <pub-id pub-id-type="doi">10.5853/jos.2023.02719</pub-id>, <pub-id pub-id-type="pmid">38836265</pub-id></mixed-citation></ref>
<ref id="ref18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Tullio</surname><given-names>MR</given-names></name> <name><surname>Jin</surname><given-names>Z</given-names></name> <name><surname>Russo</surname><given-names>C</given-names></name> <name><surname>Elkind</surname><given-names>MSV</given-names></name> <name><surname>Rundek</surname><given-names>T</given-names></name> <name><surname>Yoshita</surname><given-names>M</given-names></name> <etal/></person-group>. <article-title>Patent foramen ovale, subclinical cerebrovascular disease, and ischemic stroke in a population-based cohort</article-title>. <source>J Am Coll Cardiol</source>. (<year>2013</year>) <volume>62</volume>:<fpage>35</fpage>&#x2013;<lpage>41</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jacc.2013.03.064</pub-id>, <pub-id pub-id-type="pmid">23644084</pub-id></mixed-citation></ref>
<ref id="ref19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shah</surname><given-names>AH</given-names></name> <name><surname>Horlick</surname><given-names>EM</given-names></name> <name><surname>Kass</surname><given-names>M</given-names></name> <name><surname>Carroll</surname><given-names>JD</given-names></name> <name><surname>Krasuski</surname><given-names>RA</given-names></name></person-group>. <article-title>The pathophysiology of patent foramen ovale and its related complications</article-title>. <source>Am Heart J</source>. (<year>2024</year>) <volume>277</volume>:<fpage>76</fpage>&#x2013;<lpage>92</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ahj.2024.08.001</pub-id>, <pub-id pub-id-type="pmid">39134216</pub-id></mixed-citation></ref>
<ref id="ref20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elgendy</surname><given-names>AY</given-names></name> <name><surname>Saver</surname><given-names>JL</given-names></name> <name><surname>Amin</surname><given-names>Z</given-names></name> <name><surname>Boudoulas</surname><given-names>KD</given-names></name> <name><surname>Carroll</surname><given-names>JD</given-names></name> <name><surname>Elgendy</surname><given-names>IY</given-names></name> <etal/></person-group>. <article-title>Proposal for updated nomenclature and classification of potential causative mechanism in patent foramen Ovale-associated stroke</article-title>. <source>JAMA Neurol</source>. (<year>2020</year>) <volume>77</volume>:<fpage>878</fpage>&#x2013;<lpage>86</lpage>. doi: <pub-id pub-id-type="doi">10.1001/jamaneurol.2020.0458</pub-id>, <pub-id pub-id-type="pmid">32282016</pub-id></mixed-citation></ref>
<ref id="ref21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gwak</surname><given-names>DS</given-names></name> <name><surname>Ryu</surname><given-names>WS</given-names></name> <name><surname>Schellingerhout</surname><given-names>D</given-names></name> <name><surname>Chung</surname><given-names>J</given-names></name> <name><surname>Kim</surname><given-names>HR</given-names></name> <name><surname>Jeong</surname><given-names>SW</given-names></name> <etal/></person-group>. <article-title>Effects of white matter hyperintensity burden on functional outcome after mild versus moderate-to-severe ischemic stroke</article-title>. <source>Sci Rep</source>. (<year>2024</year>) <volume>14</volume>:<fpage>22567</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41598-024-71936-9</pub-id>, <pub-id pub-id-type="pmid">39343768</pub-id></mixed-citation></ref>
<ref id="ref22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Griffanti</surname><given-names>L</given-names></name> <name><surname>Jenkinson</surname><given-names>M</given-names></name> <name><surname>Suri</surname><given-names>S</given-names></name> <name><surname>Zsoldos</surname><given-names>E</given-names></name> <name><surname>Mahmood</surname><given-names>A</given-names></name> <name><surname>Filippini</surname><given-names>N</given-names></name> <etal/></person-group>. <article-title>Classification and characterization of periventricular and deep white matter hyperintensities on MRI: a study in older adults</article-title>. <source>NeuroImage</source>. (<year>2018</year>) <volume>170</volume>:<fpage>174</fpage>&#x2013;<lpage>81</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.neuroimage.2017.03.024</pub-id>, <pub-id pub-id-type="pmid">28315460</pub-id></mixed-citation></ref>
<ref id="ref23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Signoriello</surname><given-names>E</given-names></name> <name><surname>Cirillo</surname><given-names>M</given-names></name> <name><surname>Puoti</surname><given-names>G</given-names></name> <name><surname>Signoriello</surname><given-names>G</given-names></name> <name><surname>Negro</surname><given-names>A</given-names></name> <name><surname>Koci</surname><given-names>E</given-names></name> <etal/></person-group>. <article-title>Migraine as possible red flag of PFO presence in suspected demyelinating disease</article-title>. <source>J Neurol Sci</source>. (<year>2018</year>) <volume>390</volume>:<fpage>222</fpage>&#x2013;<lpage>6</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jns.2018.04.042</pub-id>, <pub-id pub-id-type="pmid">29801894</pub-id></mixed-citation></ref>
<ref id="ref24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Purandare</surname><given-names>N</given-names></name> <name><surname>Oude Voshaar</surname><given-names>RC</given-names></name> <name><surname>McCollum</surname><given-names>C</given-names></name> <name><surname>Jackson</surname><given-names>A</given-names></name> <name><surname>Burns</surname><given-names>A</given-names></name></person-group>. <article-title>Paradoxical embolisation and cerebral white matter lesions in dementia</article-title>. <source>Br J Radiol</source>. (<year>2008</year>) <volume>81</volume>:<fpage>30</fpage>&#x2013;<lpage>4</lpage>. doi: <pub-id pub-id-type="doi">10.1259/bjr/90498392</pub-id>, <pub-id pub-id-type="pmid">17998278</pub-id></mixed-citation></ref>
<ref id="ref25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Severa</surname><given-names>G</given-names></name> <name><surname>Cortese</surname><given-names>R</given-names></name> <name><surname>Covelli</surname><given-names>A</given-names></name> <name><surname>Battaglini</surname><given-names>M</given-names></name> <name><surname>Zhang</surname><given-names>J</given-names></name> <name><surname>Lucchetti</surname><given-names>L</given-names></name> <etal/></person-group>. <article-title>White matter lesion characteristics on MRI can differentiate multiple sclerosis from patent foramen ovale</article-title>. <source>J Neurol Sci</source>. (<year>2021</year>) <volume>429</volume>:<fpage>118301</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jns.2021.118301</pub-id></mixed-citation></ref>
<ref id="ref26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boro&#x0144;czyk</surname><given-names>M</given-names></name> <name><surname>Zdu&#x0144;ska</surname><given-names>A</given-names></name> <name><surname>W&#x0119;grzynek-Gallina</surname><given-names>J</given-names></name> <name><surname>Grodzka</surname><given-names>O</given-names></name> <name><surname>Lasek-Bal</surname><given-names>A</given-names></name> <name><surname>Domitrz</surname><given-names>I</given-names></name></person-group>. <article-title>Migraine and stroke: correlation, coexistence, dependence &#x2013; a modern perspective</article-title>. <source>J Headache Pain</source>. (<year>2025</year>) <volume>26</volume>:<fpage>39</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s10194-025-01973-w</pub-id>, <pub-id pub-id-type="pmid">39979846</pub-id></mixed-citation></ref>
<ref id="ref27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>JW</given-names></name> <name><surname>Kim</surname><given-names>SJ</given-names></name> <name><surname>Yoon</surname><given-names>CW</given-names></name> <name><surname>Park</surname><given-names>CH</given-names></name> <name><surname>Kang</surname><given-names>KW</given-names></name> <name><surname>Kim</surname><given-names>SK</given-names></name> <etal/></person-group>. <article-title>Association between the amount of right-to-left shunt and infarct patterns in patients with cryptogenic embolic stroke: a transcranial Doppler study</article-title>. <source>Int J Stroke</source>. (<year>2013</year>) <volume>8</volume>:<fpage>657</fpage>&#x2013;<lpage>62</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.1747-4949.2012.00846.x</pub-id>, <pub-id pub-id-type="pmid">22812924</pub-id></mixed-citation></ref>
<ref id="ref28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>K</given-names></name> <name><surname>Wang</surname><given-names>BZ</given-names></name> <name><surname>Hao</surname><given-names>Y</given-names></name> <name><surname>Song</surname><given-names>S</given-names></name> <name><surname>Pan</surname><given-names>M</given-names></name></person-group>. <article-title>The correlation between migraine and patent foramen Ovale</article-title>. <source>Front Neurol</source>. (<year>2020</year>) <volume>11</volume>:<fpage>543485</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fneur.2020.543485</pub-id>, <pub-id pub-id-type="pmid">33335507</pub-id></mixed-citation></ref>
<ref id="ref29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al-Hashel</surname><given-names>JY</given-names></name> <name><surname>Alroughani</surname><given-names>R</given-names></name> <name><surname>Gad</surname><given-names>K</given-names></name> <name><surname>Al-Sarraf</surname><given-names>L</given-names></name> <name><surname>Ahmed</surname><given-names>SF</given-names></name></person-group>. <article-title>Risk factors of white matter hyperintensities in migraine patients</article-title>. <source>BMC Neurol</source>. (<year>2022</year>) <volume>22</volume>:<fpage>159</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12883-022-02680-8</pub-id>, <pub-id pub-id-type="pmid">35488255</pub-id></mixed-citation></ref>
<ref id="ref30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kruit</surname><given-names>MC</given-names></name> <name><surname>van Buchem</surname><given-names>MA</given-names></name> <name><surname>Hofman</surname><given-names>PA</given-names></name> <name><surname>Bakkers</surname><given-names>JT</given-names></name> <name><surname>Terwindt</surname><given-names>GM</given-names></name> <name><surname>Ferrari</surname><given-names>MD</given-names></name> <etal/></person-group>. <article-title>Migraine as a risk factor for subclinical brain lesions</article-title>. <source>JAMA</source>. (<year>2004</year>) <volume>291</volume>:<fpage>427</fpage>&#x2013;<lpage>34</lpage>. doi: <pub-id pub-id-type="doi">10.1001/jama.291.4.427</pub-id>, <pub-id pub-id-type="pmid">14747499</pub-id></mixed-citation></ref>
<ref id="ref31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>W</given-names></name> <name><surname>Cheng</surname><given-names>Z</given-names></name> <name><surname>Fu</surname><given-names>F</given-names></name> <name><surname>Zhan</surname><given-names>Z</given-names></name></person-group>. <article-title>Prevalence and clinical characteristics of white matter hyperintensities in migraine: a meta-analysis</article-title>. <source>Neuroimage Clin</source>. (<year>2023</year>) <volume>37</volume>:<fpage>103312</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.nicl.2023.103312</pub-id>, <pub-id pub-id-type="pmid">36610309</pub-id></mixed-citation></ref>
<ref id="ref32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dalkara</surname><given-names>T</given-names></name> <name><surname>Nozari</surname><given-names>A</given-names></name> <name><surname>Moskowitz</surname><given-names>MA</given-names></name></person-group>. <article-title>Migraine aura pathophysiology: the role of blood vessels and microembolisation</article-title>. <source>Lancet Neurol</source>. (<year>2010</year>) <volume>9</volume>:<fpage>309</fpage>&#x2013;<lpage>17</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S14744422(09)70358-8</pub-id></mixed-citation></ref>
<ref id="ref33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sacco</surname><given-names>S</given-names></name> <name><surname>Harriott</surname><given-names>AM</given-names></name> <name><surname>Ayata</surname><given-names>C</given-names></name> <name><surname>Ornello</surname><given-names>R</given-names></name> <name><surname>Bagur</surname><given-names>R</given-names></name> <name><surname>Jimenez-Ruiz</surname><given-names>A</given-names></name> <etal/></person-group>. <article-title>Microembolism and other links between migraine and stroke: clinical and pathophysiologic update</article-title>. <source>Neurology</source>. (<year>2023</year>) <volume>100</volume>:<fpage>716</fpage>&#x2013;<lpage>26</lpage>. doi: <pub-id pub-id-type="doi">10.1212/WNL.0000000000201699</pub-id>, <pub-id pub-id-type="pmid">36522158</pub-id></mixed-citation></ref>
<ref id="ref34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>D&#x00F6;nmez-Demir</surname><given-names>B</given-names></name> <name><surname>Yemisci</surname><given-names>M</given-names></name> <name><surname>K&#x0131;l&#x0131;&#x00E7;</surname><given-names>K</given-names></name> <name><surname>G&#x00FC;rsoy-&#x00D6;zdemir</surname><given-names>Y</given-names></name> <name><surname>S&#x00F6;ylemezo&#x011F;lu</surname><given-names>F</given-names></name> <name><surname>Moskowitz</surname><given-names>M</given-names></name> <etal/></person-group>. <article-title>Microembolism of single cortical arterioles can induce spreading depression and ischemic injury; a potential trigger for migraine and related MRI lesions</article-title>. <source>Brain Res</source>. (<year>2018</year>) <volume>1679</volume>:<fpage>84</fpage>&#x2013;<lpage>90</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.brainres.2017.11.023</pub-id>, <pub-id pub-id-type="pmid">29183666</pub-id></mixed-citation></ref>
</ref-list>
<fn-group>
<fn fn-type="custom" custom-type="edited-by" id="fn0003">
<p>Edited by: <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/496971/overview">Claudia Altamura</ext-link>, Fondazione Policlinico Campus Bio-Medico, Italy</p>
</fn>
<fn fn-type="custom" custom-type="reviewed-by" id="fn0004">
<p>Reviewed by: <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1754595/overview">Massimiliano Faustino</ext-link>, SS Annunziata Polyclinic Hospital, Italy</p>
<p><ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/3274729/overview">Marilena Marcosano</ext-link>, Campus Bio-Medico University Hospital, Italy</p>
</fn>
</fn-group>
<fn-group>
<fn id="fn0001"><label>1</label><p><ext-link xlink:href="http://www.R-project.org/" ext-link-type="uri">http://www.R-project.org/</ext-link></p></fn>
</fn-group>
</back>
</article>